The dopamine agonist, phno ((+)-4-propyl-9-hydroxynaphthoxazine), inhibits cyclic adenosine 3', 5'-monophosphate formation and prolactin release from anterior pituitary cells
- 1 June 1989
- journal article
- research article
- Published by Elsevier in Neuropharmacology
- Vol. 28 (6) , 647-650
- https://doi.org/10.1016/0028-3908(89)90145-7
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Attenuation of Anterior Pituitary Phosphoinositide Phosphorylase Activity by the D2Dopamine Receptor*Endocrinology, 1988
- Dopaminergic reduction of intracellular calcium: The role of calcium influxBiochemical and Biophysical Research Communications, 1988
- Activation of calcium channels by MaitotoxinPublished by Elsevier ,1987
- (+)-4-PROPYL-9-HYDROXYNAPHTHOXAZINE (PHNO), A NEW DOPAMINOMIMETIC, IN TREATMENT OF PARKINSONISMThe Lancet, 1985
- CHARACTERIZATION OF DOPAMINE-RECEPTORS MEDIATING INHIBITION OF ADENYLATE-CYCLASE ACTIVITY IN RAT STRIATUM1985
- PHARMACOLOGIC PROFILE OF A NOVEL POTENT DIRECT-ACTING DOPAMINE AGONIST, "(+)-4-PROPYL-9-HYDROXYNAPHTHOXAZINE [(+)-PHNO]1984
- Pertussis toxin uncouples dopamine agonist inhibition of prolactin releaseAmerican Journal of Physiology-Endocrinology and Metabolism, 1983
- Gammaflow: A Completely Automated Radioimmunoassay SystemScience, 1976